Cancer Drugs’ High Prices Possibly Not Justified by Cost of R&D

Researchers from MSK and the Oregon Health and Science University sought to find out the approximate cost to bring a cancer drug to market. Their study, published in JAMA Internal Medicine (09/11/17), sought to quantify a standard amount by focusing on new cancer drugs and analyzing the company filings with the Securities and Exchange Commission to determine research and development costs. Although the new study was small, its estimates found the median cost was below previous estimates while profits were in the tens of billions. Dr. Sham Mailankody from MSK commented in an NPR article about their findings.